



FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2013

1. Headlines

A\$M	Constant Currency*	Constant Currency increase on previous year	Statutory	Statutory increase on previous year
Revenue	3,502	4.7%	3,484	4.1%
EBITDA pre USA 'cost-out' implementation costs	655	4.9%	649	4.0%
EBITDA	652	4.5%	647	3.6%
Net Profit	338	7.1%	335	6.0%

- Record revenue and earnings results
- EBITDA margins
 - Pathology margin ex-USA and UK up 40 basis points (“bps”)
 - Imaging margin up 80 bps
 - IPN margin up 80 bps
- US\$60M p.a. cost-out initiative underway in USA
- Final Dividend 37¢ per share, 45% franked, Record date: 4 September 2013, Payment date: 24 September, 2013.
- Total dividend payout up 5% to 62 cents per share
- FY2014 guidance: Approximately 5% EBITDA growth (Constant Currency). Equates to approximately 12% growth at current exchange rates.

2. Commentary on Results

Sonic Healthcare today reported a record net profit for the year to 30 June 2013 of A\$335 million, a 7% increase over the prior year on a constant currency basis. The result was achieved on revenues of A\$3,484 million, 5% higher on a constant currency basis.

Sonic’s CEO, Dr Colin Goldschmidt, said: “Sonic Healthcare has continued its long record of consistent revenue and earnings growth in 2013. The company is strong and stable, and well positioned for future revenue and profit growth in attractive healthcare markets. We are delighted to reward shareholders with a significantly higher final dividend.”

Dr Goldschmidt pointed to Sonic’s market leading positions in eight countries as a major advantage, particularly with the increasing demand for diagnostic services arising from growing and ageing populations, new tests and preventative medicine. He also noted the increasing trend for governments to outsource their diagnostic testing to the private sector in order to address growing healthcare costs. “Sonic’s unique culture and values are clear market differentiators which drive growth by acquisition and organically, including contract opportunities. Doctors, hospitals and healthcare funders increasingly recognise the value in Sonic’s medical leadership philosophy and the company’s singular focus on providing the highest quality services to clinicians, patients and other customers.”

Dr Goldschmidt added: “Our deeply embedded culture fosters passion in the organisation and also helps to make us an employer of choice, with very low turnover of staff, particularly at management, pathologist and radiologist levels. I wish to thank all of our 26,000 employees for their ongoing dedication and for their contribution towards Sonic’s success.”

Dr Colin Goldschmidt
CEO
Sonic Healthcare Limited
Ph.: (02) 9855 5333
Fax: (02) 9878 5066

For further information regarding the result, please refer to Dr Goldschmidt’s PowerPoint Presentation and to Sonic’s Appendix 4E Preliminary Final Report, both of which will be posted on the Sonic Healthcare website by 10.00am, 20 August 2013 (www.sonichealthcare.com).

* **Constant Currency:** Current period results presented using the same currency exchange rates as used in the comparative period to translate offshore earnings. For more details see Appendix 4E Preliminary Final Report.

Forward-looking statements

This media release may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts and unexpected growth in costs and expenses. The statements being made in this media release do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Sonic Healthcare). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements.